Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

Background: Molecular targeted therapies are the most important type of medical treatment for GIST, but the development of GIST drugs and their targets have not been summarized. Methods: Drugs in the field of GIST were analyzed and collated through Pharmaprojects, ClinicalTrials. gov and PharmaGO databases. Results: As of 2021, there are 75 drugs that have appeared in the GIST clinical trials. The six most frequent targets in GIST clinical trials, in descending order of frequency, were KIT, PDGFRA, KDR (VEGFR2), FLT3, FLT1 (VEGFR1), and FLT4/VEGFR3. Only 8 drugs are in preclinical research. There are challenges in the development of new drugs for GIST. Conclusion: This article analyzes and summarizes the general situation of GIST drugs, the target distribution of GIST drugs, and the trends in GIST drug-related clinical trials.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/1567201820666221122120657
2024-01-01
2025-01-28
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/1567201820666221122120657
Loading

  • Article Type:
    Research Article
Keyword(s): clinical trials; GIST; pharmaprojects; targeted therapy; therapeutic targets; TKI
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test